Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus TRAVASOL 8 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus TRAVASOL 8 5 W O ELECTROLYTES.
AMINOSYN 8.5% (PH6) vs TRAVASOL 8.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% (pH 6) provides a mixture of essential and nonessential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral or enteral nutrition.
TRAVASOL 8.5% W/O ELECTROLYTES provides amino acids for protein synthesis, serving as a source of nitrogen and essential amino acids to support anabolism and prevent catabolism in patients unable to tolerate oral or enteral nutrition.
1-1.5 g amino acids/kg/day intravenously, typically 500 mL of a 8.5% solution (42.5 g amino acids) infused over 8-24 hours.
Intravenous infusion; 500 mL to 1 L per day, administered at a rate of 100-200 mL/hour. Dosage depends on protein and calorie requirements, typically 0.8-1.5 g/kg/day of amino acids.
None Documented
None Documented
Not applicable as a fixed value; elimination half-life of individual amino acids varies (minutes to hours) and is dependent on metabolic demand and renal function.
Not applicable as a single value; amino acids have variable half-lives (minutes to hours) depending on individual metabolic demand and plasma concentration; continuous infusion achieves steady state rapidly.
Primarily renal; elimination depends on metabolic utilization. Unused amino acids are deaminated and excreted as urea in urine (over 90%). Fecal elimination is negligible.
Primarily eliminated via metabolic pathways (hepatic deamination and transamination) with nitrogenous waste excreted renally as urea; negligible biliary/fecal excretion of unchanged amino acids.
Category C
Category C
Amino Acid Solution
Amino Acid Solution